Activation of glucocorticoid receptor signaling inhibits KSHV-induced inflammation and tumorigenesis
IMPORTANCE: Kaposi's sarcoma (KS) is the most common cancer in HIV-infected patients caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Hyperinflammation is the hallmark of KS. In this study, we have shown that KSHV mediates hyperinflammation by inducing IL-1α and suppressing IL-1Ra. Mechanistically, KSHV miRNAs and vFLIP induce hyperinflammation by activating the NF-κB pathway. A common anti-inflammatory agent dexamethasone blocks KSHV-induced hyperinflammation and tumorigenesis by activating glucocorticoid receptor signaling to suppress IL-1α and induce IL-1Ra. This work has identified IL-1-mediated inflammation as a potential therapeutic target and dexamethasone as a potential therapeutic agent for KSHV-induced malignancies.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
mBio - 15(2024), 1 vom: 16. Jan., Seite e0301123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Luping [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic UpdateOf: bioRxiv. 2023 Nov 14;:. - PMID 38014281 Citation Status MEDLINE |
|---|
| doi: |
10.1128/mbio.03011-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366077589 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366077589 | ||
| 003 | DE-627 | ||
| 005 | 20240205232000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/mbio.03011-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM366077589 | ||
| 035 | |a (NLM)38117084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Luping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Activation of glucocorticoid receptor signaling inhibits KSHV-induced inflammation and tumorigenesis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Nov 14;:. - PMID 38014281 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: Kaposi's sarcoma (KS) is the most common cancer in HIV-infected patients caused by Kaposi's sarcoma-associated herpesvirus (KSHV) infection. Hyperinflammation is the hallmark of KS. In this study, we have shown that KSHV mediates hyperinflammation by inducing IL-1α and suppressing IL-1Ra. Mechanistically, KSHV miRNAs and vFLIP induce hyperinflammation by activating the NF-κB pathway. A common anti-inflammatory agent dexamethasone blocks KSHV-induced hyperinflammation and tumorigenesis by activating glucocorticoid receptor signaling to suppress IL-1α and induce IL-1Ra. This work has identified IL-1-mediated inflammation as a potential therapeutic target and dexamethasone as a potential therapeutic agent for KSHV-induced malignancies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IL-1 receptor antagonist (IL-1Ra) | |
| 650 | 4 | |a Kaposi’s sarcoma (KS) | |
| 650 | 4 | |a Kaposi’s sarcoma-associated herpesvirus (KSHV) | |
| 650 | 4 | |a NF-κB | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a glucocorticoid receptor (GR) signaling | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a interleukin-1 alpha (IL-1α) | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a Receptors, Glucocorticoid |2 NLM | |
| 700 | 1 | |a Ding, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xian |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yufei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shou-Jiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mBio |d 2010 |g 15(2024), 1 vom: 16. Jan., Seite e0301123 |w (DE-627)NLM200128191 |x 2150-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:16 |g month:01 |g pages:e0301123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/mbio.03011-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 16 |c 01 |h e0301123 | ||